Complete Genomics Pops after Illumina Takeover News

Loading...
Loading...
Shares of Complete Genomic
GNOM
are seeing much strength after Roche's announced a hostile takeover of Illumnia last night. Roche
RHHBY
announced yesterday that it is proposing to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis. This offer represents a 64% premium over Illumina's stock price on December 21, 2011 – the day before market rumors about a potential transaction between Roche and Illumina drove Illumina's stock price significantly higher – a 61% premium over the one-month historical average and a 43% premium over the three-month historical average of Illumina's share price, both as of December 21. Illumina is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets. Complete Genomics has a similar business, in which it is a life sciences company that developes and commercializes a deoxyribonucleic acid [DNA] sequencing platform. Its complete genomics analysis platform Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Currently, shares of Complete Genomics are trading up about 14% at $2.85.
Loading...
Loading...
Posted In: NewsRumorsFDAM&APre-Market OutlookMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...